XPH:ARCA-SPDR S&P Pharmaceuticals

ETF | Health | NYSE Arca

Last Closing Price

USD 45.29

Change

-0.45 (-0.98)%

Market Cap

USD 0.41B

Volume

0.15M

Yahoo Analyst Target

N/A

STA Analyst Target

N/A
Yahoo Analyst Rating

N/A

STA Analyst Rating

N/A

STA Verdict

Verdict

About

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Inception Date: 19/06/2006

Primary Benchmark: S&P Pharms Select Industry TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.35%

Management Expense Ratio: 0.35 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV SPDR Select Sector Fund - Heal.. 0.14 %

+0.43 (+0.50%)

USD 17.56B
VHT Vanguard Health Care 0.10 %

+0.25 (+0.15%)

USD 7.51B
XBI SPDR Series Trust S&P Biotech 0.35 %

-2.78 (-3.10%)

USD 4.61B
IYH iShares U.S. Healthcare 0.44 %

+0.62 (+0.34%)

USD 2.04B
IXJ iShares Global Healthcare 0.48 %

+0.06 (+0.05%)

USD 1.70B
IHI iShares U.S. Medical Devices 0.44 %

-0.58 (-0.32%)

USD 1.58B
FBT First Trust Amex Biotech Index.. 0.56 %

-2.94 (-2.22%)

USD 1.28B
FXH First Trust Health Care AlphaD.. 0.62 %

-0.34 (-0.46%)

USD 1.04B
HQH Tekla Healthcare Investors 0.00 %

-0.10 (-0.42%)

USD 0.97B
FHLC Fidelity MSCI Health Care Inde.. 0.08 %

+0.09 (+0.21%)

USD 0.97B

ETFs Containing XPH

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health)
Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.11% 43% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.11% 43% F 70% C-
Trailing 12 Months  
Capital Gain 14.14% 29% F 61% D-
Dividend Return 0.74% 38% F 7% F
Total Return 14.87% 21% F 57% F
Trailing 5 Years  
Capital Gain 51.62% 25% F 66% D
Dividend Return 5.03% 35% F 12% F
Total Return 56.65% 10% F 62% D-
Average Annual (5 Year Horizon)  
Capital Gain 7.17% 39% F 66% D
Dividend Return 7.83% 29% F 55% F
Total Return 0.67% 43% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 26.62% 18% F 24% F
Risk Adjusted Return 29.43% 18% F 33% F
Market Capitalization 0.50B 39% F 39% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.